Patents Assigned to Medgenics Medical Israel Ltd.
-
Publication number: 20190030128Abstract: Micro-organ compositions and methods of implanting into the central nervous system (CNS) for the treatment of CNS-related diseases are encompassed. Specifically, the disclosure provides methods for treating disorders including cancer and lysosomal storage diseases, the methods comprising implanting a micro-organ into the CNS, wherein the micro-organ secretes a recombinant protein, and wherein the micro-organ is maintained in the CNS, and secretes protein, for at least seven days.Type: ApplicationFiled: January 10, 2017Publication date: January 31, 2019Applicant: Medgenics Medical Israel Ltd.Inventors: Garry NEIL, Nir SHAPIR, Reem MIARI
-
Patent number: 9687564Abstract: The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.Type: GrantFiled: October 16, 2014Date of Patent: June 27, 2017Assignee: Medgenics Medical Israel Ltd.Inventors: Andrew L. Pearlman, Baruch S. Stern
-
Publication number: 20170143374Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for harvesting the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Exemplary embodiments of the invention provide a genetically modified dermal micro-organ expressing at least one recombinant gene product. Some embodiments of the invention provide methods and apparatuses for implanting a genetically modified DMO.Type: ApplicationFiled: February 6, 2017Publication date: May 25, 2017Applicant: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Alex Okun, Yaron Fuerst, David Shalhevet, Elisha Amir, Mordechay Bukhman
-
Patent number: 9572593Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for harvesting the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO to from the skin-related tissue structure. Exemplary embodiments of the invention provide a genetically modified dermal micro-organ expressing at least one recombinant gene product. Some embodiments of the invention provide methods and apparatuses for implanting a genetically modified DMO.Type: GrantFiled: July 1, 2015Date of Patent: February 21, 2017Assignee: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Alex Okun, Yaron Fuerst, David Shalhevet, Elisha Amir, Mordechay Bukhman
-
Patent number: 9468667Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure.Type: GrantFiled: June 30, 2013Date of Patent: October 18, 2016Assignee: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Itzhak Lippin, Guillermo Alberto Piva, Lior Rosenberg, Mordechay Bukhman, Baruch S. Stern, David Shalhevet, Menachem D. Shavitt, Andrew L. Pearlman, Noam Shani, Einat Almon
-
Publication number: 20160122713Abstract: Provided herein is a genetically-modified micro-organ that provides a sustained delivery of a therapeutic peptide. The genetically-modified micro-organ may comprise a viral vector or expression cassette comprising at least two nucleic acid sequences encoding the therapeutic peptide separated by a cleavable linker. Further provided herein is a method of treating or preventing a disease or disorder in a human subject that can be treated or prevented by administration of a therapeutic peptide over a sustained time period using the genetically-modified micro-organ described herein.Type: ApplicationFiled: October 13, 2015Publication date: May 5, 2016Applicant: MEDGENICS MEDICAL ISRAEL LTD.Inventors: Nir Shapir, Garry Neil, Amos Panet, Reem Miari
-
Publication number: 20160051627Abstract: The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha.Type: ApplicationFiled: July 17, 2015Publication date: February 25, 2016Applicant: Medgenics Medical Israel Ltd.Inventors: Andrew L. Pearlman, Baruch S. Stern
-
Publication number: 20160000457Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for harvesting the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO to from the skin-related tissue structure. Exemplary embodiments of the invention provide a genetically modified dermal micro-organ expressing at least one recombinant gene product. Some embodiments of the invention provide methods and apparatuses for implanting a genetically modified DMO.Type: ApplicationFiled: July 1, 2015Publication date: January 7, 2016Applicant: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Alex Okun, Yaron Fuerst, David Shalhevet, Elisha Amir, Mordechay Bukhman
-
Publication number: 20150313623Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure.Type: ApplicationFiled: July 8, 2015Publication date: November 5, 2015Applicant: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Itzhak Lippin, Guillermo Alberto Piva, Lior Rosenberg, Mordechay Bukhman, Baruch S. Stern, David Shalhevet, Menachem D. Shavitt, Andrew L. Pearlman, Noam Shani, Einat Almon
-
Patent number: 9155749Abstract: The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha.Type: GrantFiled: September 12, 2007Date of Patent: October 13, 2015Assignee: Medgenics Medical Israel Ltd.Inventors: Andrew L. Pearlman, Baruch S. Stern
-
Patent number: 9127084Abstract: The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.Type: GrantFiled: June 15, 2011Date of Patent: September 8, 2015Assignee: Medgenics Medical Israel Ltd.Inventors: Andrew L. Pearlman, Baruch S. Stern
-
Patent number: 9107896Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure.Type: GrantFiled: February 9, 2012Date of Patent: August 18, 2015Assignee: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Itzhak Lippin, Guillermo Alberto Piva, Lior Rosenberg, Mordechay Bukhman, Baruch S. Stern, David Shalhevet, Menachem D. Shavitt, Andrew L. Pearlman, Noam Shani, Einat Almon
-
Patent number: 9101595Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for harvesting the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Exemplary embodiments of the invention provide a genetically modified dermal micro-organ expressing at least one recombinant gene product. Some embodiments of the invention provide methods and apparatuses for implanting a genetically modified DMO.Type: GrantFiled: December 2, 2012Date of Patent: August 11, 2015Assignee: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Alex Okun, Yaron Fuerst, David Shalhevet, Elisha Amir, Mordechay Bukhman
-
Publication number: 20150118187Abstract: The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a nucleic acid sequence operably linked to one or more regulatory sequences. The present invention is further directed to methods providing sustained expression of therapeutic polypeptides and prolonged therapeutic effects, such as erythropoietin and interferon.Type: ApplicationFiled: October 22, 2014Publication date: April 30, 2015Applicant: MEDGENICS MEDICAL ISRAEL LTD.Inventors: Nir Shapir, Reem Miari, Baruch S. Stern, Shany Blum, Avi Rimler
-
Publication number: 20150110743Abstract: The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.Type: ApplicationFiled: October 16, 2014Publication date: April 23, 2015Applicant: MEDGENICS MEDICAL ISRAEL LTD.Inventors: Andrew L. Pearlman, Baruch S. Stern
-
Patent number: 8877175Abstract: The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.Type: GrantFiled: February 26, 2013Date of Patent: November 4, 2014Assignee: Medgenics Medical Israel Ltd.Inventors: Andrew Pearlman, Baruch S. Stern
-
Patent number: 8771291Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for harvesting the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Exemplary embodiments of the invention provide a genetically modified dermal micro-organ expressing at least one recombinant gene product. Some embodiments of the invention provide methods and apparatuses for implanting a genetically modified DMO.Type: GrantFiled: November 28, 2012Date of Patent: July 8, 2014Assignee: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Alex Okun, Yaron Fuerst, David Shalhevet, Elisha Amir, Mordechay Bukhman
-
Patent number: 8685635Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure.Type: GrantFiled: October 22, 2012Date of Patent: April 1, 2014Assignee: Medgenics Medical Israel Ltd.Inventors: Stephen F. Bellomo, Itzhak Lippin, Guillermo Alberto Piva, Lior Rosenberg, Mordechay Bukhman, Baruch S. Stern, David Shalhevet, Menachem D. Shavitt, Andrew L. Pearlman, Noam Shani, Einat Almon
-
Patent number: 8586024Abstract: The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha.Type: GrantFiled: June 30, 2011Date of Patent: November 19, 2013Assignee: Medgenics Medical Israel Ltd.Inventors: Andrew L. Pearlman, Baruch S. Stern
-
Publication number: 20130251679Abstract: The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.Type: ApplicationFiled: February 26, 2013Publication date: September 26, 2013Applicant: MEDGENICS MEDICAL ISRAEL LTD.Inventors: ANDREW PEARLMAN, BARUCH S. STERN